On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
We have now added a new section called the "Assay History List" to the "At A Gla...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...